Display options
Cite
Cross M, Bach E, Tran T, et al. Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia. Onco Targets Ther. 2013;6:741-8doi: 10.2147/OTT.S45459.
Cross, M., Bach, E., Tran, T., Krahl, R., Jaekel, N., Niederwieser, D., Junghanss, C., Maschmeyer, G., & Al-Ali, H. K. (2013). Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia. OncoTargets and therapy, 6741-8. https://doi.org/10.2147/OTT.S45459
Cross, Michael, et al. "Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia." OncoTargets and therapy vol. 6 (2013): 741-8. doi: https://doi.org/10.2147/OTT.S45459
Cross M, Bach E, Tran T, Krahl R, Jaekel N, Niederwieser D, Junghanss C, Maschmeyer G, Al-Ali HK. Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia. Onco Targets Ther. 2013 Jun 20;6:741-8. doi: 10.2147/OTT.S45459. Print 2013. PMID: 23836986; PMCID: PMC3699298.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2013 Jun 20;6:741-8. doi: 10.2147/OTT.S45459. Print 2013.

Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia.

OncoTargets and therapy

Michael Cross, Enrica Bach, Thao Tran, Rainer Krahl, Nadja Jaekel, Dietger Niederwieser, Christian Junghanss, Georg Maschmeyer, Haifa Kathrin Al-Ali

Affiliations

  1. Division of Hematology and Oncology, University of Leipzig, Leipzig, Germany.

PMID: 23836986 PMCID: PMC3699298 DOI: 10.2147/OTT.S45459

Abstract

BACKGROUND: Epigenetic modulations, including changes in DNA cytosine methylation, are implicated in the pathogenesis and progression of acute myeloid leukemia (AML). Azacitidine is a hypomethylating agent that is incorporated into RNA as well as DNA. Thus, there is a rationale to its use in patients with AML. We determined whether baseline and/or early changes in the methylation of long interspersed element (LINE)-1 or CDH13 correlate with bone marrow blast clearance, hematological response, or survival in patients with AML treated with azacitidine.

METHODS: An open label, phase I/II trial was performed in 40 AML patients (median bone marrow blast count was 42%) unfit for intensive chemotherapy treated with azacitidine 75 mg/m(2)/day subcutaneously for 5 days every 4 weeks. Bone marrow mononuclear cell samples were taken on day 0 (pretreatment) and day 15 during the first treatment cycle; LINE-1 and CDH13 methylation levels were quantified by methylation-specific, semiquantitative, real-time polymerase chain reaction.

RESULTS: Treatment with azacitidine significantly reduced LINE-1 but not CDH13 methylation levels over the first cycle (P < 0.0001). Absolute LINE-1 methylation levels tended to be lower on day 0 (P = 0.06) and day 15 of cycle 1 (P = 0.03) in patients who went on to achieve subsequent complete remission, partial remission or hematological improvement versus patients with stable disease. However, the decrease in LINE-1 methylation over the first treatment cycle did not correlate with subsequent response (P = 0.31). Baseline methylation levels of LINE-1 or CDH13 did not correlate with disease-related prognostic factors, including cytogenetic risk, relapsed/refractory AML, or presence of NPM1 or FLT3 mutations. No correlation was observed between LINE-1 or CDH13 methylation levels and overall survival.

CONCLUSION: Analysis of baseline LINE-1 methylation levels may help identify elderly AML patients who are most likely to respond to azacitidine therapy.

Keywords: CDH13; DNA methylation; LINE-1 methylation; acute myeloid leukemia; azacitidine; clinical response

References

  1. Lancet Oncol. 2009 Mar;10(3):223-32 - PubMed
  2. Blood. 2008 Aug 15;112(4):1366-73 - PubMed
  3. Blood. 2001 Sep 1;98(5):1312-20 - PubMed
  4. J Clin Oncol. 2010 Feb 1;28(4):562-9 - PubMed
  5. Haematologica. 2006 Nov;91(11):1513-22 - PubMed
  6. Blood. 2009 Sep 24;114(13):2764-73 - PubMed
  7. Cancer Res. 2006 Jun 15;66(12):6361-9 - PubMed
  8. Oncogene. 2002 Aug 12;21(35):5483-95 - PubMed
  9. Blood. 2010 Jan 7;115(1):107-21 - PubMed
  10. Clin Cancer Res. 2009 Jun 15;15(12):3938-46 - PubMed
  11. Blood. 2012 Sep 20;120(12):2466-74 - PubMed
  12. Cancer. 2007 Mar 15;109(6):1114-24 - PubMed
  13. Leukemia. 2007 Sep;21(9):1937-44 - PubMed
  14. Cancer Cell. 2010 Jan 19;17(1):13-27 - PubMed
  15. PLoS One. 2012;7(3):e33213 - PubMed
  16. Cancer Res. 2006 May 15;66(10):5495-503 - PubMed
  17. J Clin Oncol. 2003 Apr 15;21(8):1472-9 - PubMed
  18. J Oncol. 2010;2010:943823 - PubMed
  19. Cancer. 2007 Jul 15;110(2):345-52 - PubMed
  20. Blood. 2012 May 31;119(22):5229-38 - PubMed
  21. CA Cancer J Clin. 2002 Nov-Dec;52(6):363-71 - PubMed
  22. Blood. 2009 Apr 30;113(18):4179-87 - PubMed
  23. Blood. 1999 Oct 1;94(7):2445-51 - PubMed
  24. Leuk Lymphoma. 2012 Jan;53(1):110-7 - PubMed
  25. Cancer. 2006 Mar 1;106(5):1090-8 - PubMed
  26. J Clin Oncol. 2003 Dec 15;21(24):4642-9 - PubMed
  27. Oncogene. 2005 Nov 3;24(48):7213-23 - PubMed
  28. Cancer. 2012 Feb 15;118(4):1014-22 - PubMed
  29. Cancer Res. 2009 Oct 15;69(20):8127-32 - PubMed
  30. Cancer Res. 1970 Nov;30(11):2760-9 - PubMed
  31. J Clin Oncol. 2002 May 15;20(10):2441-52 - PubMed
  32. Cancer Biol Ther. 2004 Oct;3(10):1007-17 - PubMed
  33. J Clin Oncol. 2012 Jul 20;30(21):2670-7 - PubMed
  34. Br J Haematol. 2007 Jan;136(1):96-105 - PubMed
  35. PLoS One. 2010 Feb 02;5(2):e9001 - PubMed
  36. J Korean Med Sci. 2011 Feb;26(2):207-13 - PubMed

Publication Types